Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article from the last 30 days matching "hematologic malignancy risk"

GrantNIH REPORTERMay 11

New NIH Grant: The RUNX1 Research Program 10th Annual Scientific Conference and Patient Meeting — $10K at Unknown Institution

The National Institutes of Health is funding a conference bringing together researchers, doctors, and patients with RUNX1-FPD, a rare blood disorder where people have a high risk of developing blood cancers. The conference aims to help experts share what they know and work together to improve care and research for this condition.

WHY IT MATTERSThis conference creates a dedicated space for RUNX1-FPD patients and families to connect with leading researchers and clinicians studying their specific condition, which is critical since many people with this disorder face a 35-50% lifetime risk of developing blood cancer.
Good to knowRUNX1 familial platelet disorder with predisposition to hematologic malignanciesRUNX1-FPDFPDMM

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases